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Abstract 
Background: Mother-to-child transmission (MTCT) of HIV continues to fuel the the HIV 
epidemic in resource-limited countries, especially in sub-Saharan Africa. To minimize MTCT, 
the World Health Organization (WHO) recommends a range of therapy guidelines – including 
Options B and B-Plus. Option B indicates that HIV-positive pregnant women in developing 
countries who are early in disease progression receive antiretroviral therapy (ART) during 
pregnancy and breastfeeding. An enhanced therapy recommendation, Option B-Plus, advises that 
all HIV-positive pregnant women initiate lifetime ART during their first pregnancy, regardless of 
disease progression. This study seeks to compare health outcomes and cost-effectiveness of 
adopting Option B-Plus versus Option B in Ghana. 
 
Methods: A retrospective review of 817 medical records of HIV-infected women treated at two 
hospitals in Kumasi, Ghana was performed to obtain clinical values, including baseline CD4 
count, fertility rate, and timing of antenatal care access, that were used in analysis. Using 
additional data from published literature, including changes in CD4 count and HIV-related costs, 
a decision-analytic model was developed to estimate quality-adjusted life expectancy for mothers 
and all future children following Option B-Plus or Option B. The model captures the probability 
of MTCT prenatally and during breastfeeding, both in the current and future pregnancies. 
Additional ART and healthcare cost calculations were performed to compare the cost-
effectiveness of the regimens. Sensitivity analyses on model parameters were performed. 
Outcome values were evaluated against WHO benchmarks for cost-effectiveness. 
 
Results: The average age at first pregnancy was 22.8 years (SD 5.0) and women had an average 
of 2.3 children (SD 1.3). Option B costs 6,038 USD over a woman’s lifetime and yields 9.8 
quality-adjusted life years (QALYs) to the mother and 62.2 QALYs to each child. Option B-Plus 
costs 16,727 USD and yields 16.3 QALYs to the mother and 67.6 QALYs to each child. 
Compared to Option B, Option B-Plus costs 625 USD per QALY gained, which would be 
considered “very cost-effective” by WHO benchmarks. If implemented on a national level, 
Option B-Plus could prevent nearly 1,000 HIV infections among children in Ghana each year, 
compared to Option B. 
 
Results: Option B-Plus substantially reduces MTCT in current and future pregnancies, and is a 
very cost-effective use of limited resources. This cost-effectiveness remained over robust 
sensitivity analyses. Further, Option B-Plus demonstrates a substantial increase in both maternal 
and children QALYs. We recommend the implementation of policies supporting Option B-Plus 
in Ghana and other resource-limited countries affected by HIV. 
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Introduction 
Global efforts to reduce mother-to-child transmission (MTCT) of HIV have made substantial 
progress with 400,000 fewer new infections occurring in children between 2009 and 2011, in 
large part due to improved access to antiretroviral therapy (ART) among pregnant women (1). 
Despite this considerable progress, approximately 13% of all new HIV infections occur among 
children, with 330,000 children newly infected each year, 90% of whom live in sub-Saharan 
Africa (1). To achieve an “AIDS-Free Generation,” programs that improve access to treatment 
for HIV-positive pregnant women must be prioritized. 
In Ghana, the prevalence of HIV among adults aged 15 to 49 is approximately 1.8% (2). In 
addition to those adults, nearly 30,000 children who were infected from MTCT are now living 
with HIV (1). HIV prevalence among pregnant women in Ghana ranges from 2.0-4.2% (2, 3). 
MTCT can occur during pregnancy, birth, or breastfeeding, yet much of this transmission is 
preventable with appropriate treatment (4). In 2011, 64% of pregnant women in Ghana received 
ART to reduce the incidence of MTCT, a substantial increase from just 28% in 2009 (5). With 
more than 80% of pregnant women having access to antenatal care, achieving the Millennium 
Development Goal of reducing or eliminating MTCT by 2015 is within reach in Ghana (6, 7). 
Rates of MTCT in Ghana of HIV vary between studies, but range from 14-42%, depending 
largely on access and adherence to treatment(8). Current World Health Organization (WHO) 
recommendations endorse antiretroviral prophylaxis that begins early in gestation and continues 
through breastfeeding stages for women with a CD4 cell count above 350 cells/mm
3
, and   
recommend lifetime ART for women with a CD4 cell count below 350 cells/mm
3
. These 
guidelines, commonly known as “Option B,” have the potential to reduce rates of MTCT to as 
low as 1%, assuming high access to antenatal services (9). Option B has the potential to 
significantly reduce MTCT and improve the health of HIV-positive mothers, yet it is 
significantly more expensive than the previously recommended prevention option of a single 
dose of Nevirapine during delivery (9). 
Although Option B improves HIV-positive maternal health outcomes, more extensive regimens 
with fewer treatment interruptions between pregnancies may provide greater benefits. An 
enhanced recommendation, commonly referred to as “Option B-Plus,” proposes that all HIV-
positive pregnant women receive lifelong ART beginning at first pregnancy to improve overall 
health outcomes, regardless of CD4 cell count. This strategy may improve maternal health 
through reduced morbidity and mortality, and reduce overall MTCT, especially in settings with 
high fertility rates(10). Avoiding HIV infection in children reduces HIV-related mortality and the 
subsequent costs of pediatric HIV care. Option B-Plus may be challenging to implement in 
resource-limited settings like Ghana and further evaluation is needed to assess its budgetary 
impact and cost-effectiveness. In this study, we summarize primary data collected from two 
hospitals in Ghana. A key component of our analyses is the inclusion of all pregnancies likely to 
occur in a woman’s lifetime. To the best of our knowledge, no prior study has included 
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pregnancy recurrence in cost-effectiveness evaluation of Option B-Plus. Including pregnancy 
recurrence in a model fully captures the impact of therapy regimens on HIV-positive women in 
developing countries, many of whom have more than one child. We utilized data collected onsite 
with epidemiologic, demographic, and clinical data from previous studies, and apply a decision-
analytic model to evaluate the costs, health benefits – to both the mother and children – and cost-
effectiveness of Option B versus Option B-Plus in Ghana. The primary objective of this analysis 
is to evaluate the cost-effectiveness of these two guidelines and a secondary objective is to utilize 
cost-effectiveness information to inform global recommendations for HIV therapy among 
pregnant women in resource-limited countries like Ghana. 
Methods 
We developed a state-transition model to compare the lifetime costs and benefits of two 
strategies to prevent MTCT in Ghana. When possible, data were collected from local Ghanaian 
sources. Ages of pregnancy and antenatal care access patterns were obtained from a review of 
medical charts of HIV-positive women at two government hospitals in Kumasi, Ghana (Table 1). 
Transmission rates, life expectancies, adherence rates and HIV care access patterns were 
obtained through documents issued by the Ghana Health Service. Costs, utilities, CD4 change 
patterns, CD4 testing patterns, and resistance values were obtained through previously published 
studies. 
Patient Characteristics 
The patient population included in the model is HIV-positive pregnant women in Ghana, who are 
pregnant with their first child. The chart review consisted of abstracting data from paper medical 
charts at two government hospitals in Kumasi, Ghana. These hospitals serve a range of women 
from Kumasi and its surrounding region. Their patient bases were considered demonstrative of 
the overall population by representatives from the Ghana Health Service. 
Based on the chart review of HIV-positive pregnant women, estimates of average baseline CD4 
count at time of antenatal care were obtained. Age of first pregnancy, lifetime number of 
children per woman, and time between successive pregnancies were also estimated through chart 
review. Maternal life expectancy was evaluated using medical charts and death records at each 
hospital. 
Definition of Options 
Option B and Option B-Plus are two of three options recommended for the prevention of MTCT 
by the WHO. Under both options, an HIV-positive woman who has CD4 count less than 350 
cells/mm
3 
is pregnant, she is immediately treated with a triple-ART that continues through life. 
However, under Option B, women with CD4 count greater than 350 cells/mm
3
 receive ART 
beginning at 14 weeks into gestation and continued throughout pregnancy and after birth until 
breastfeeding ceases. Alternatively, under Option B-Plus, all women receive lifetime ART, even 
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if CD4 count is greater than 350 cells/mm
3
. Under both options, infants born to HIV-positive 
women receive daily ART from birth through the age of 4-6 weeks(11). 
Model Parameters 
Fertility Rates 
A key consideration when evaluating the cost-effectiveness of continual ART versus interrupted 
therapy is the time between successive pregnancies. Because Option B implies that a pregnant 
woman ceases ART following completion of breastfeeding, she may not receive ART at the 
optimal starting point (the end of the first trimester) of her next pregnancy, especially because 
only 12% of women in our sample received antenatal care during their first trimester. With 
Option B-Plus, she remains continually on ART, so there is no window during a pregnancy when 
she is not receiving prophylactic therapy. 
Based on medical chart review, a hazard model was fit to estimate the rate and time distribution 
of future pregnancies following the first pregnancy. Each pregnancy recorded from the chart 
review was considered an event and the age at which these events occurred was included in the 
model. This hazard model produced the probability of a pregnancy occurring at each age in a 
woman’s lifetime. The model was developed in SAS 9.3. 
Access to Antenatal Care, Adherence, and Transmission 
The overall fraction of pregnant women in Ghana who receive antenatal care at some point in 
their pregnancy was determined based on a national survey (6). In more detailed analysis, the 
proportions of pregnant women who accessing antenatal care, by month of pregnancy, were 
estimated through medical chart review. Estimates of ART adherence and the probability of 
mother-to-child transmission during pregnancy, delivery, or while breastfeeding were obtained 
from annual reports on antenatal care and MTCT issued by the Ghana Health Service (6, 12). 
Under Option B, a woman who does not qualify for lifetime therapy at their first pregnancy (by 
having a CD4 cell count < 350 cells/mm
3
) can initiate ART during her lifetime when her CD4 
cell count decreases below 350 cells/mm
3
 (9). Our model accounts for this by tracking CD4 cell 
count throughout a woman’s lifetime and initiating ART when the 350 cells/mm3 threshold is 
reached. 
Reports on transmission rates among women receiving Option B consider ideal conditions (i.e., a 
pregnant woman receives therapy from the beginning of her first trimester through six months of 
breastfeeding).However, these ideal conditions are not achievable if antenatal care is obtained 
beyond the first trimester of pregnancy. To achieve a more realistic transmission rate on Option 
B, we multiplied the percentage of women accessing antenatal care during a specific month of 
pregnancy – the values for which were obtained through chart review – by a scaled rate of 
transmission. This scaled rate of MTCT was determined by considering an ideal rate of 1.0% if a 
woman accessed antenatal care in the first 3 months of pregnancy, and gradually increasing rates 
if care was accessed in each subsequent month, with a 20.3% rate of MTCT under the least ideal 
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conditions (access to antenatal care in the 9
th
 month of pregnancy). See the Appendix for a more 
detailed depiction of data used in this value generation. 
Quality of life Adjustments, Costs, CD4 Changes, and other Parameters 
Additional values not obtained through chart review were acquired through review of previously 
published studies. All costs are reported in US Dollars (1 USD = 1.93 Ghana Cedi, abbreviated 
as GHS) and incorporate all facets of HIV/AIDS care following diagnosis, including ART, 
medical personnel wages, and CD4 count and viral load testing. In particular, we assume the 
annual cost of HIV/AIDS care with first-line ART to be 385 USD (744 GHS), but we consider 
variations of this assumption in sensitivity analysis (13, 14). 
Changes in CD4 cell count were modeled from previously published works and the rate of CD4 
change was determined by a woman’s ART utilization and whether ART is interrupted or 
continuous (15-17). Women incurred a CD4 cell count increase of 153 cells/mm
3
 at the initiation 
of therapy (18). Adjustments for quality of life while living with HIV were considered on as a 
yearly quality adjustment for adults and a lifetime adjustment for children. Adult women living 
with HIV were assumed to have 0.8 times the quality of life of otherwise healthy women (19). 
Children born HIV-positive were attributed this same 0.8 quality of life adjustment, applied 
across life expectancy and discounted by an annual discount rate of 0.3 (20, 21). 
Model Structure, Outcomes & Analysis 
The state-transition model was developed in TreeAge Pro (2012 version). The model tracks a 
woman’s age, CD4 count, and number of past pregnancies when evaluating transition 
probabilities to future states. Similar to Markov models, our model incorporates several states 
with transition probabilities between each state. However, values like CD4 count and number of 
previous pregnancies may impact these transition probabilities, thereby not following the 
assumed memoryless property of a Markov model, in which all transition probabilities are 
independent of past or current states. 
The health states of the model were “Pregnant,” “Breastfeeding HIV+ Child,” “Breastfeeding 
HIV- Child,” “Not Pregnant”, and “Dead”, where certain transition probabilities between states 
differed between treatment regimens.  A basic model schematic is shown in Figure 1. Each cycle 
of the model represented 3 months of time. Sensitivity analyses were conducted on several 
variables. Ranges utilized in the sensitivity analyses are indicated in Table 1.  
Primary outcomes of the model were costs and quality-adjusted life years (QALYs) for each 
therapy option.  All costs and QALYs are discounted to the present using a 3% annual discount 
rate (22). Costs and QALYs of Option B and Option B Plus were then compared using an 
incremental cost-effectiveness ratio (ICER):  
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ICER values are measured in cost per QALY gained under Option B-Plus compared to Option B. 
These values were compared to benchmarks established by the WHO Commission on 
Macroeconomics for Health. These benchmarks indicate that a cost-effective alternative to 
current guidelines has an ICER value of less than 3 times the country’s gross domestic product 
(GDP) per capita. An alternative recommendation with ICER less than 1 times the country’s 
GDP per capita is considered “very cost-effective” (23). The GDP per capita in Ghana was 3,300 
USD (6,369 GHS) in 2012 (24). 
Results 
Population Demographics 
During the chart review, 817 medical charts were reviewed – 418 at Suntreso Government 
Hospital and 399 at Kumasi South Hospital. Key results of this chart review are trimester during 
which women access antenatal care, age of first pregnancy, and average number of children. The 
average age of first pregnancy was 22.78 years (± 4.97 years) and the average lifetime number of 
children per woman was 2.34 (± 1.27 children). Among women whose timing of antenatal care 
access was known, 12% accessed care in their first trimester, 40% in their second trimester, and 
48% in their third trimester. Detailed results of this chart review can be found in Table 1. 
Pregnancy Recurrence 
The hazard model established probability of pregnancy at each age following a woman’s first 
pregnancy. The probability associated with a second pregnancy at each year following the first 
pregnancy, as taken directly from chart review data, can be found in Figure 2. Approximately 
32% of the women in our sample did not have a second pregnancy, while 4% became pregnant 
within one year following their first pregnancy and 19% became pregnant within two years. The 
average time between the first and second pregnancies was 4.56 years (± 3.05 years). 
Reduction in Mother-to-Child Transmission 
Approximately 10,800 births occur to HIV-positive women in Ghana each year (25). Under 
Option B, HIV transmission rate is 10.19% during pregnancy or delivery and 1% during 
breastfeeding, suggesting that approximately 1,209 new cases of HIV are due to MTCT each 
year. Under Option B-Plus, HIV transmission rate is 1% during pregnancy or delivery and 1% 
during breastfeeding, resulting in 216 new MTCT HIV cases each year. Thus, offering all 
pregnant women in Ghana Option B-Plus instead of Option B could theoretically prevent 993 
HIV cases among newborn babies in Ghana each year. 
Cost-Effectiveness 
Option B has lifetime cost of 6,038 USD while Option B-Plus has a lifetime cost of 16,727 USD. 
Option B yields 11.91 QALYs to the mother and Option B-Plus yields 16.28 QALYs, an 
increase of 35%. Further, Option B yields 62.17 QALYs per child, while Option B-Plus yields 
67.57 QALYs per child. Considering the QALYs attributed to the mother in addition to the 
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QALYs collectively attributed to all of the mother’s children, Option B yields 165.2 QALYs and 
Option B-Plus yields 182.3 total QALYs. These values lead to an incremental cost-effectiveness 
ratio (ICER) of 625.1 USD per QALY gained. If quality-of-life weights are ignored, an ICER 
value of 1,039 USD per life-year gained is obtained. Table 3 contains detailed baseline results of 
the primary outcomes. 
Sensitivity Analyses 
A detailed sensitivity analysis was performed on all model parameters, to test for robustness and 
identify key parameters impacting cost-effectiveness results. Of all variables examined, cost-
effectiveness was most sensitive to the probability of MTCT during pregnancy or delivery under 
Option B. However, even when this probability was decreased to 0%, the model’s ICER value 
was only 1,553 USD per QALY gained, which is still below the Ghanaian GDP per capita of 
3,300 USD. This increase in ICER is likely due to transmission rates among the two options 
becoming more similar, thus decreasing the cost-effectiveness of Option B-Plus as compared to 
Option B. 
A tornado diagram (Figure 3) shows that the cost-effectiveness of Option B-Plus was also 
sensitive to specific variables in the model including life expectancies, cost of HIV care with 
first-line ART, access to antenatal care, and fertility rates. 
One-way sensitivity analyses of several variables display each variable’s relationship to the 
model ICER value (Figure 4). As the probability of accessing antenatal care is increased from 
0.50 to 0.95, Option B-Plus becomes more cost-effective compared to Option B, yet ICER values 
only reach 1,108 USD per QALY gained. Similarly, ICER values decrease as the fertility rate in 
the model is ranged from 0.75 to nearly 5 children born to an HIV-positive woman, but the ICER 
only ranges from 507-874 USD per QALY gained over this range of fertility rate. Finally, as life 
expectancy on Option B is modified from 6-30 remaining life years after first pregnancy, ICER 
values increase approximately linearly. As women are estimated to live longer under Option B, 
their life expectancies are not only more similar to the life expectancies under Option B-Plus, 
thereby making Option B less cost-effective compared to Option B-Plus. 
Discussion 
The goal of this analysis was to evaluate the cost-effectiveness of Option B versus Option B-Plus 
therapy regimens among HIV-positive pregnant women in Ghana. Option B-Plus improves both 
maternal and child outcomes, and we find that the additional cost of such a program is likely 
warranted given its favorable cost-effectiveness. Option B-Plus helps ensure that women who 
would otherwise not initiate ART until the second or third trimester under Option B can receive 
continual therapy during their index pregnancy and all subsequent pregnancies. Our model was 
unique in its ability to account for multiple pregnancies. Our study also has important 
implications for helping policymakers allocate limited HIV resources effectively and efficiently. 
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A secondary objective was to inform global policy on recommendations for HIV therapy among 
pregnant women in resource-limited countries. Our results indicate that although Option B costs 
approximately one-third the cost of Option B Plus, the latter yields approximately 17 more 
QALYs to the mother and her children. 
Comparing Option B Plus to Option B, we obtain an ICER value of 625 USD per QALY gained 
(1,206 GHS per QALY gained). This value is in line with other HIV interventions shown to be 
cost-effective in low- and middle-income countries, such as male circumcision in sub-Saharan 
Africa (26-28).The 2012 gross domestic product per capita in Ghana was approximately 3,300 
USD (6,369 GHS) (24). Based on recommendations by the WHO Commission on 
Macroeconomics in Health, Option B Plus is considered very cost-effective compared to Option 
B (23). Additionally our sensitivity analysis demonstrates that our cost-effectiveness results were 
robust to wide ranges of parameter assumptions, which suggests that Option B-Plus is very likely 
cost-effective in a setting with similar resources and epidemiologic characteristics to Ghana. Our 
results are generally consistent with other studies that use model-based analyses to estimate the 
cost-effectiveness of Option B-Plus in Zimbabwe and Nigeria (9, 29). These previous analyses 
provide significant contributions to understanding the cost-effectiveness of Option B-Plus and 
our analysis expands this understanding further by incorporating the opportunity for multiple 
pregnancies over a woman’s lifetime as well as primary data utilization. Our findings are also 
consistent with other cost-effectiveness analyses of HIV prevention methods in Ghana, including 
voluntary HIV counseling and blood donation screening (8, 30).  
An outcome not directly related to this model that is critical to consider for larger policy 
implications is the percentage of HIV-positive pregnant women who qualify for lifetime therapy 
according to recommendations from the WHO Commission on Macroeconomics for Health (23). 
As Table 1 indicates, 52.9% of HIV-positive pregnant women qualify for lifetime therapy at the 
time of their first pregnancy. Considering this figure, the overall cost to scale up to Option B-
Plus throughout the country is less expensive. 
Our modeling study has several limitations. First, because Option B Plus is a newly devised 
intervention, updates on its efficacy and impact on maternal disease progression and survival are 
evolving; however, we have explored variations in parameter assumptions with robust sensitivity 
analysis. Second, the model does not explicitly consider horizontal HIV transmission; however, 
we believe this is a valid assumption because an HIV-positive pregnant woman likely has a 
regular partner who is also HIV-positive (31).  We also estimated the expected costs and QALYs 
associated with Option B and Option B Plus, but the model simplifies complex clinical 
outcomes, such as viral load, development of opportunistic infections, or variability in HIV 
progression in children. Future projects related to this analysis could include comparing MTCT 
rates, by the trimester during which a mother first accesses antenatal care under Option B. 
Although our model captures this variability in transmission, more precise values should be 
examined. 
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In resource-limited settings such as Ghana, systematically comparing the potential health 
benefits and costs of competing HIV programs can illuminate where additional investment 
should be prioritized. Option B-Plus provides considerable health benefits to HIV-positive 
women and their children, even when opportunities for multiple pregnancies are considered, and 
represents good value. With wide implementation of Option B-Plus, we estimate that 
approximately 1,000 more children could potentially be born without HIV in Ghana every year, 
and preventing these infections now is a key step towards reducing the burden of HIV in the 
future.  
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Tables and Figures 
Table 1. Population Demographics 
Parameter Value (Standard Deviation or % of total)* 
Charts Reviewed 817 
Suntreso Government Hospital 418 (51.2%) 
Kumasi South Hospital 399 (48.8%) 
Age of first pregnancy 22.78 years (±4.97 years) 
Number of children (HIV+) 2.34 children (±1.27 children) 
Number of children (overall) 4.12 children** 
Pregnant when diagnosed HIV-positive 223 (27.3%) 
Baseline CD4 count 471 cells/mm
3
 
CD4 <350 cells/mm
3
 when pregnant and 
diagnosed 
118 (52.9%) 
Known timing of pregnancy when first 
accessing care (n=92) 
 
1
st
 trimester 11 (12.0%) 
Month 1 1 (1.1%) 
Month 2 4 (4.4%) 
Month 3 6 (6.5%) 
2
nd
 trimester 37 (40.2%) 
Month 4 11 (12.0%) 
Month 5 14 (15.2%) 
Month 6 12 (13.0%) 
3
rd
 trimester 44 (47.8%) 
Month 7 19 (20.7%) 
Month 8 19 (20.7%) 
Month 9 6 (6.5%) 
*Percentages may not add to 100% due to rounding. 
**Source: United States Central Intelligence Agency World Factbook(24) 
Table 2. Model Parameters 
Variable Base-Case Value Range Source 
Demographic variables    
Maternal life expectancy    
Option B 40 years 28-52 years Ghana Health Service(6) 
Option B Plus 56 years 44-68 years Ghana Health Service(6) 
Number of children 2.34 1-5 Chart review 
    
Probabilities    
Access to care 82% 50-95% Ghana Health Service(6) 
Access to CD4 testing 33% 20-60% When To Start Consortium 
(32) 
Adherence to ART 90% 50-95% Ghana Health Service(6) 
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Resistance to ART after 
stopping therapy 
40% - Ghana Health Service(12) 
Transmission during 
pregnancy 
   
No therapy/non-
adherence 
22% 15-30% Ghana Health Service(12), 
De Cock 2000 (33) 
Option B 10%
Ϯ
 0-15% Ghana Health Service(12) 
Option B-Plus 1% 0-5% Ghana Health Service(12) 
Transmission during 
breastfeeding 
   
No therapy/non-
adherence 
10% 5-20% Ghana Health Service(12), 
De Cock 2000 (33) 
Option B 1% 0-5% Ghana Health Service(12) 
Option B-Plus 1% 0-5% Ghana Health Service(12) 
    
Changes to CD4 Count    
No therapy (every 3 
months) 
- 12.75 cells/mm
3
 5-20 cells/ 
mm
3
 
Fidler 2007(16), Holmes 
2006(17) 
Initiate therapy + 153 cells/mm
3 
100-400 
cells/mm
3
 
Deeks 1999(18) 
Continue therapy (every 3 
months) 
   
Previously interrupted 
therapy 
-0.063659* 
[Current CD4] 
- Ickovics et al. 2001(15) 
Continuous therapy - 0.0099853* 
[Current CD4]
 
- Ickovics et al. 2001(15) 
 
 
  
Costs (USD[GHS])    
Mother (Annual Cost of 
HIV Care) 
   
Care with First-Line 
ART 
385.45 [743.91] 191-580.31 WHO 2011(14); Rosen, J., 
and F. Asante. 2010(13) 
Care with Second-Line 
ART 
848.33 [1,637.28] - WHO 2011(14); Rosen, J., 
and F. Asante. 2010(13) 
Child HIV Care (Lifetime 
costs) 
10,665.49 
[20,584.40] 
5,181-15,544 WHO 2011(14); Rosen, J., 
and F. Asante. 2010(13) 
    
Utility    
HIV-positive adult 
(quality of life) 
0.8 0.50-1.0 Tengs T.O., Lin T.H. 
2002(19) 
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HIV-positive child 
(lifetime QALYs)  
20.2
ϮϮ
 10-30 UN Impact of AIDS 
2004(20) 
HIV-negative child 
(lifetime QALYs) 
62.7 50-70 UN Impact of AIDS 
2004(20) 
    
Discount rate 0.03 0.00-0.05 Weinstein et al. 1996(21) 
*Sensitivity analyses performed on age of first pregnancy were performed by changing values manually 
due to variable structure in the decision-analytic model. 
Ϯ
 Probability of transmission during pregnancy/delivery while on Option B was determined by applying 
the distribution of when women accessed antenatal care (found through chart review) with ideal 
conditions of Option B (beginning therapy at the beginning of the second trimester) indicated by the 
Ghana Health Service and WHO. 
Ϯ Ϯ
 Lifetime QALYs for an HIV-positive child assume a life expectancy at birth of 47.1 years (Source: UN 
“The Impact of AIDS” publication 2004) with a yearly utility of 0.82 and a discount rate of 0.03. 
 
Table 3. Baseline Results of Primary Outcomes 
Treatment 
Strategy 
Lifetime 
Cost (GHS) 
Lifetime 
Cost (USD) 
Life-
Years* 
QALYs*
 Ϯ
 ICER*
Ϯ
 
Option B 11,654 6,038 186.4 165.2  
Mother 2,424 1,256 11.9 9.8  
Children 9,230 4,783 174.5 155.4  
Per Child 3, 692 1,913 69.8 62.2  
Option B-Plus 32,283 16,727 196.7 182.3 625.1 
Mother 19,230 9,964 16.3 13.4  
Children 13,053 6,763 180.4 168.9  
Per Child 5,221 2,705 72.2 67.6  
*All life-years/QALYs discounted by 3% annual rate. 
Ϯ
 QALY = Quality-Adjusted Life-Year; ICER = Incremental Cost-Effectiveness Ratio. All 
QALYs are calculated using an adjustment of 0.82 utility per year when living with symptomatic 
HIV and an annual discount rate of 0.03. The ICER value is calculated as follows: 
ICER=([CostB-Plus-CostB]/[QALYB-Plus-QALYB]). 
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Figure 1. State Transition Model Overview 
 
 
Figure 2. Probability of time between 1
st
 and 2
nd
 pregnancy 
 
*
0 years since first pregnancy indicates the mother does not have more than one child.
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Figure 3. Tornado Diagram 
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Figure 4. One-Way Sensitivity Analyses 
 
 = Base Case
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Appendix 
Chart Review – Full Results 
 N  (% of total) 
Total 817 (100%) 
Location (n=817)  
Suntreso Government Hospital 418 (51.2%) 
Kumasi South Hospital 399 (48.8%) 
Pregnancy Status (n=588)  
Pregnant 221 (37.6%) 
Not pregnant 367 (62.4%) 
First Access of Antenatal Care (n=92)  
First trimester 11 (12.0%) 
Second trimester 37 (43.5%) 
Third trimester 44 (47.8%) 
Age (n=811)  
18-24 64 (8.1%) 
25-29 186 (23.4%) 
30-34 179 (22.5%) 
35-39 138 (17.4%) 
40-44 85 (10.7%) 
45-49 54 (6.8%) 
50+ 88 (11.1%) 
Marital Status (n=804)  
Single 100 (12.4%) 
Cohabiting 111 (13.8%) 
Married 383 (47.6%) 
Separated 30 (3.7%) 
Divorced 85 (10.6%) 
Widow 95 (11.8%) 
Occupational Status (n=807)  
Full Time 614 (76.1%) 
Part Time 10 (1.2%) 
On Leave 13 (1.6%) 
Unemployed 170 (21.1%) 
Education Level (n=795)  
Nil 162 (20.4%) 
Primary 155 (19.5%) 
JSS/MSLC 391 (49.2%) 
Sec/Tech 65 (8.2%) 
Tertiary 22 (2.8%) 
Vertical Transmission (n=641)  
Positive 25 (3.9%) 
Negative 50 (7.8%) 
Positive/Negative 5 (0.8%) 
Don't Know 561 (87.5%) 
HIV Type (n=453)  
Type I 411 (90.7%) 
Type II 7 (1.5%) 
Types I/II 35 (7.7%) 
HIV Symptoms (n=738)   
0 137 (18.6%) 
1 160 (21.7%) 
2 107 (14.5%) 
3 106 (14.4%) 
4 88 (11.9%) 
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Calculation of Option B Transmission Rate 
Month of ANC 
access 
1 2 3 4 5 6 7 8 9 
% of women in 
population 
(pmonth) 
1.1 4.3 6.5 12.0 15.2 13.0 20.7 20.7 6.5 
MTCT 
probability 
(ratemonth) 
1.0 1.0 1.0 2.8 6.3 9.8 13.3 16.8 20.3 
                           ∑                 
 
         
5 79 (10.7%) 
6+ 61 (8.3%) 
Other Diseases (n=770)  
0 278 (36.1%) 
1 276 (35.8%) 
2 130 (16.9%) 
3+ 86 (11.2%) 
Sexually Active (n=417) 346 (66.9%) 
Contraception Use (n=323) 130 (40.2%) 
Contraception Type (n=189)  
Condoms 151 (79.9%) 
Injection 28 (14.8%) 
Pill 10 (5.3%) 
Diagnosis Year (n=811)  
2005 6 (0.7%) 
2006 23 (2.8%) 
2007 130 (16.0%) 
2008 162 (20.0%) 
2009 248 (30.6%) 
2010 149 (18.4%) 
2011 72 (8.9%) 
2012 21 (2.6%) 
Disclosure (n=746) 609 (81.6%) 
WHO Status (n=718)  
I 181 (25.2%) 
II 158 (22.0%) 
III 296 (41.2%) 
IV 83 (11.6%) 
On ART (n=761) 597 (78.4%) 
Malaria (n=770) 278 (36.1%) 
Tuberculosis (n=770) 40 (5.2%) 
Sexually Transmitted Infection 
(n=770) 
57 (10.9%) 
Respiratory Tract Infection (n=770) 84 (7.4%) 
Depression (n=770) 13 (1.7%) 
Anemia (n=770) 66 (8.6%) 
Hypertension (n=770) 31 (4.0%) 
Heart Disease (n=770) 16 (2.1%) 
Gastrointestinal Disease (n=770) 34 (4.4%) 
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